Literature DB >> 10586385

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.

D K Yu1.   

Abstract

P-glycoprotein (PGP) is well known because of its contribution to multiple-drug resistance during anticancer treatment. More recent work indicates that PGP mediates the transcellular transport of many drugs in addition to anticancer compounds. Because of this reason, its potential role in clinically significant drug-drug interactions has just begun to be realized. This article provides an overview of published in vitro, in situ, and in vivo drug-drug interaction results that are related to PGP transport so that the awareness of the scientific community can be heightened. In addition, several recommendations are made to take full advantage of the recently published data.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586385     DOI: 10.1177/00912709922012006

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  43 in total

Review 1.  Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?

Authors:  W K Kraft; S A Waldman
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Herb-drug interactions: review and assessment of report reliability.

Authors:  A Fugh-Berman; E Ernst
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

3.  Interaction of flucloxacillin and quinidine.

Authors:  W J Comuth; J A Comuth; R N W Hauer; M M Malingré
Journal:  Eur J Clin Pharmacol       Date:  2011-12-28       Impact factor: 2.953

Review 4.  Diuretics in pediatrics : current knowledge and future prospects.

Authors:  Maria M J van der Vorst; Joana E Kist; Albert J van der Heijden; Jacobus Burggraaf
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 5.  Safety and efficacy of statins in Asians.

Authors:  James K Liao
Journal:  Am J Cardiol       Date:  2006-12-15       Impact factor: 2.778

Review 6.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

7.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

Review 8.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

9.  Characterization and application of a vinblastine-selected CACO-2 cell line for evaluation of p-glycoprotein.

Authors:  Dennis A Laska; Jack O Houchins; Susan E Pratt; Jeffery Horn; Xialong Xia; Brenda R Hanssen; Daniel C Williams; Anne H Dantzig; Terry Lindstrom
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002 Jul-Aug       Impact factor: 2.416

10.  In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Christophe Rousselle; Marcel Debray; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.